Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine

Pharmacopsychiatry

Volumn 36, Issue 1, 2003, Pages 3-6

  Grozinger M ^a   Dragicevic, A ^a   Hiemke, C ^a   Shams, M ^a   Muller M J ^a   Härtter, Sebastian ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CLOZAPINE; CYTOCHROME P450 2D6; DESVENLAFAXINE; DEXTROMETHORPHAN; DEXTRORPHAN; LORAZEPAM; MELPERONE; O DEMETHYLASE; OLANZAPINE; PIPAMPERONE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADULT; AGED; ARTICLE; CATALYSIS; CONCENTRATION RESPONSE; DEPRESSION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INHIBITION; DRUG MONITORING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIDE EFFECT; STEADY STATE;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BUTYROPHENONES; CYCLOHEXANOLS; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHYLATION; MIDDLE AGED; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SLEEP DISORDERS;

EID: 0037242245     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-38084     Document Type: Article

References (26)

1. Benkert O, Hippius H. Kompendium der Psychiatrischen Pharmakotherapie. Berlin, Heidelberg, New York: Springer, 2001
2. Bjerkenstedt L. Melperone in the treatment of schizophrenia. Acta Psychiatr Scand Suppl 1989; 352: 35-39
3. Bjerkenstedt L, Harnyrd C, Grimm V, Gullberg B, Sedvall G. A double blind comparison of melperone and thiothixene in psychotic women using a new rating scale, the CPRS. Arch Psychiatr Nervenkr 1978; 14: 157-172
4. Borbely AA. The S-deficiency hypothesis of depression and the two-process model of sleep regulation. Pharmacopsychiat 1987; 20: 23-29
5. Borgstrom L, Larsson H, Molander L. Pharmacokinetics of parenteral and oral melperone in man. Eur J Clin Pharmacol 1982; 23: 173-176
6. Christensen I, Geismar L, Kirkegaard A, Kirkegaard G. Additional studies on side effects of melperone in long-term therapy for 1-20 years in psychiatric patients. Arzneimittelforschung 1986; 36: 855-860
7. Christensson EG. Pharmacological data of the atypical neuroleptic compound melperone (Buronil). Acta Psychiatr Scand Suppl 1989; 352: 7-15
8. Eap CB, Bertel-Caubscher R, Zullino D, Amey M, Baumann P. Marked increase of venlafaxine enatiomer concentration as a consequence of metabolic interaction: A case report. Pharmacopsychiat 2000; 33: 112-25
9. Fogelman SM, Schmider J, Venkatakrishnan K, von Moltke LL, Harmatz JS, Shader RI, Greenblatt DJ. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropharmacology 1999; 20: 480-490
10. Ford DE, Cooper-Patrick C. Sleep disturbances and mood disorders: an epidemiologic perspective. Depress Anxiety 2001; 14: 3-6
11. Halpert JR. Structural basis of selective cytochrome P450 inhibition. Annu Rev Pharmacol Toxicol 1995: 35: 29-53
12. Härtter S, Baier D, Dingemanse J, Ziegler G, Hiemke C. Automated determination of dextromethorphan and its main metabolites in human plasma by high performance-liquid chromatography and column switching. Ther Drug Monit 1996: 18: 297-303
13. Holliday SM, Benfield P. Venlafaxine: A review of its pharmacology and therapeutic potential in depression. Drugs 1995; 49: 280-294
14. Köhler D, Härtter S, Fuchs K, Sieghart W, Hiemke C. CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. Pharmacogenetics 1997; 7: 453-61
15. Kretzschmar R, Otto J, Teschendorf HJ, Worstmann W. Pharmacological investigation of 4′-fluoro-4-(4-methyl-peperodono)-butyrophenone with respect to its sedative and sleep-inducing properties. Arzneimittelforschung 1976; 26: 1073-1076
16. Küpfer A, Schmid B, Pfaff G. Pharmacogenetics of dextromethorphan O-demethylation in man. Xenobiotica 1986; 16: 421-33
17. Lessard E, Yessine M-A, Hamelin BA, O'Hara G, LeBlanc J,Turgeon J. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 1999; 9: 435-443
18. Molander L, Borgström L. Relationship between plasma concentration and arousal in normal subjects after single oral and parenteral doses of melperone, a butyrophenone neuroleptic. Psychopharmacology 1983; 79: 111-114
19. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Cin Pharmacol 1996; 41: 149-156
20. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds. Life Sci 2000; 68: 29-39
21. Salin-Pascual RJ, Galicia-Polo L, Drucker-Colin R. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers. J Clin Psychiatry 1997; 58: 348-350
22. Settle EC jr. Antidepressant drugs: disturbing and potentially dangerous adverse effects. J Cin Psychiat. 1998; 59 Suppl 16: 25-30
23. Smith DA, Jones BC. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 1992; 44: 2089-2098
24. Syvälahti AKG, Lindberg R, Kallio J, De Vocht M. Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol 1986; 22: 89-92
25. Vefkind AH, Haffmans PMJ, Hoencamp E. Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 2000; 22: 202-208
26. Weigmann H, Härtter S, Maehrlein S, Kiefer W, Krämer G, Dannhardt G, Hiemke C. Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column switching high performance liquid chromatography. J chromatogr B 2001; 759: 63-71